This study is not currently recruiting.
Description: An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and Phase 3 Double-Blind, Placebo-Controlled Phase to Assess The Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta (ULTRAGENYX)
Eligibility & Criteria
IRB #: IRB00316439
Principal Investigator: Malinda Wu, MD
Eligible Age Range: Ages 5 to 26
Gender: All
Diagnosis: Osteogenesis Imperfecta
IRB #: IRB00316439
Principal Investigator: Malinda Wu, MD
Eligible Age Range: Ages 5 to 26
Gender: All
Diagnosis: Osteogenesis Imperfecta